Albine Martin, PhD
Executive in Residence at Johns Hopkins University and BioHealth Innovation
Dr. Albine Martin brings over 20 years of operating and product commercialization experience within 3 three public companies representing the biotechnology, diagnostics and life sciences sector. She provides leadership to advance technologies from bench to market in her role as Executive in Residence at Johns Hopkins University and Biohealth Innovation. Her areas of focus include Digital Health, Diagnostics, medical devices, research tools and platform technologies. As COO of Precision Biologics, (a clinical stage oncology company) she led integration of clinical development with a Companion Diagnostic strategy. As Vice President, Compugen (CGEN), she built a revenue model incorporating consumable assets with big data and managed strategic alliances to translate computational discovery into value driven assets. During her tenure at Life Technologies [LIFE] she led a global portfolio as Senior Business Director and managed Joint Ventures and expansion within the Asia-Pacific region. She has collaborated with FDA/CBER to develop compliance standards and commercialization strategies for ancillary products and devices within the Cellular Therapy arena. She has led start up innovation through the BLA approval and commercialization of the first HPV diagnostic at Digene Diagnostics and more recently the advancement of an HIV-1 persistence assay portfolio with Accelevir Diagnostics. She is a member of the NSF commercial reviewer panels for SBIR 1/2 funding and a speaker at their annual conference. Dr. Martin holds a PhD from the University of Maryland and served as a Staff Fellow at the National Institutes of Health and holds a Certificate of Financial Management from Cornell University and is a graduate of the Program on Leadership and Strategy in Pharmaceuticals and Biotech at the Harvard Business School.